ESR1 and breast carcinoma: Furthermore, measuring ERα status in these patients, we found that BAP18 contributed to poorer survival in ERα-positive breast cancer and had minimal impact on the survival of ERα-negative breast cancer patients (Supplementary Figure S1B, C).